Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly.
Here are are a few highlights from this week:
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma (Blood) - Although nivolumab efficacy in R/R FL was limited in this study, the authors revealed important mechanistic insights into the immune response to nivolumab, demonstrating the significant influence of immune microenvironment.
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells (Blood) - This preclinical study presents a strategy to improve NK cell effector function that combines CAR engineering and gene editing of a cytokine-related immune checkpoint, a strategy that might have an impact on the future development of NK cell–based cancer immunotherapy.
- CAR T-cell therapies for patients with multiple myeloma (Nat Rev Clin Oncol) - Data from more than 20 clinical trials involving anti-BCMA CAR T-cells has demonstrated that patients with R/R MM can achieve objective responses. This comprehensive review summarizes the data available to date, describing novel antigens that could be targeted in the future, and highlighting potential future innovations to reduce toxicity associated with CAR-T cell therapies.
You can access our complete resource library of scientific publications here.